Pilot Study of Combination Therapy With CHOP-Zenapax (CHOP-daclizumab)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years to 75 Years (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Histologically confirmed ATLL requiring treatment
Frank acute leukaemia or lymphoma subtypes
Chronic and smouldering cases should be considered if they are symptomatic and require therapy, or there is evidence of disease progression
No previous treatment with anthracycline based cytotoxic chemotherapy
a. Patients may have received interferon and /or zidovudine and/or non-anthracycline based therapy
Age 18-75 years
Written informed consent
HIV 1 or 2 positivity
Pregnancy or breast-feeding
Prior hepatic or renal insufficiency with a bilirubin or transaminases greater than 5 times the normal range or a creatinine greater than 150μmol/l (not related to hypercalcaemia) following rehydration
Other concomitant neoplasms not related to HTLV-I
Cardiac or respiratory insufficiency with an ECOG score of greater than 3